Anti-viral Drugs Market Highlights

The global anti-viral drugs market is likely to touch an impressive valuation of USD 62.67 billion by 2022, predicts Market Research Future (MRFR). The report published by MRFR on the global anti-viral drugs market mentions that the market is projected to register a CAGR of 6.9% between 2013 and 2022.

Download Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/2454

Anti-viral Drugs Market Synopsis

The rising cases of viral disease is identified to boost the global anti-viral drugs market growth. The inadequacy of dietary nutrition in people, due to increase in consumption of high calorie and low fibrous food is creating favourable condition for virus to invade human body. Hence, the need for anti-viral drugs are surging as viral infections prevail. The growing incidences of HIV and other sexually-transmitted diseases are also boosting the sales number of anti-viral drugs, hence, anticipated to prompt the anti-viral drug market growth.

The increase in cases of drug resistance is propelling extensive research and developmental undertakings for launching more effective anti-viral drugs. Additionally, the stringency in drug approval stages are taking care of the quality of drugs in the pipeline. New product launches are gaining traction for revenue generation for the anti-viral drugs market. The application of anti-viral drugs in other diseases like, bird flu, and others is also likely to prompt the global anti-viral drug growth.

The expiry of patents for certain blockbuster anti-viral drug are stimulating generic drug competition in the anti-viral drug market. This is deepening the competitive scenario of the global anti-viral drug market over the assessment period.

However, adverse effects of anti-viral drugs and high price of anti-viral drugs can hinder the anti-viral drugs market growth over the assessment period.

Anti-viral Drugs Market Segmental Overview

The global anti-viral drugs market study has been segmented on the basis of application and mechanism of action.

Based on the application, the anti-viral drugs market has been segmented into Influenza, Hepatitis, Herpes, HIV/AIDS, and others.

Based on the mechanism of action, the anti-viral drugs market has been segmented into Protease Inhibitors, Nucleotide Polymerase Inhibitors, Reverse Transcriptase Inhibitors, and others.

Anti-viral Drugs Market Regional Outlook

Based on the region, the anti-viral drug market has been studied across the Americas, Asia Pacific, Europe, and the Middle East Asia.

MRFR forecasts that the anti-viral drug market in the American region is likely to hold the largest market share. The need for effective treatment of diseases due to the growing cases of viral infection in the region can bolster the anti-viral drugs market. The North American market is expected to grasp greater than 30% of the global market share. The anti-viral drugs market in Europe is likely to garner an impressive CAGR by 2022. MRFR report states that the anti-viral drugs market in Europe will hold the second largest market share over the review period. The anti-viral drug market in the Asia pacific region anticipated to register the highest CAGR over the forecast period. The anti-viral drug market in the Middle East Asia and Africa is expected to exhibit a sluggish growth.

Anti-viral Drugs Market Key Players

MRFR have enlisted some of the prominent companies operating in the anti-viral drugs market. They are; Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Gilead Sciences Inc., Cipla Inc. GlaxoSmithKline Plc, Novartis International AG, Abbott Laboratories, and Astra Zeneca AB.




Industry Updates


In October 2018, the U.S. Food and Drug Administration approved a new antiviral drug for the treatment of acute influenza in patients above the age of 12 years. Xofluza is the first new antiviral drug with a novel mechanism of action and will be helpful in the treatment of patients who have been symptomatic for not more than 48 hours.
October 2018, the results of a clinical trial of British biotech ViiV Healthcare shows that HIV could be treated with monthly antiviral injections instead of daily drugs. The antiviral two-drug combination injectable is reported to have the same viral suppression effect as three-drug combinations and reduces the risk of harmful interactions with other medication.


Browse Complete Report with Covid19 Impact @ https://www.marketresearchfuture.com/reports/anti-viral-drugs-market-2454

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: [email protected]

Blog: https://healthcarenews12.blogspot.com/